Treatment for Moderate Facial Eczema Refractory to Moderate-Potency Topical Corticosteroids

Introduction to Topical Calcineurin Inhibitors

The American Academy of Allergy, Asthma, and Immunology recommends initiating a topical calcineurin inhibitor, such as tacrolimus 0.1% ointment or pimecrolimus 1% cream, for moderate facial eczema that has failed moderate-potency topical corticosteroids and moisturizers, while continuing aggressive emollient therapy and evaluating for secondary infection or contact allergens 1
Both tacrolimus 0.1% ointment and pimecrolimus 1% cream are FDA-approved for short-term and intermittent long-term treatment in patients unresponsive to or intolerant of conventional therapies 1

The FDA black box warning regarding malignancy risk associated with topical calcineurin inhibitors is not supported by current evidence, with actual lymphoma rates lower than predicted in the general population 1

The National Institute for Health and Care Excellence recommends obtaining bacterial swabs if secondary infection is suspected, as Staphylococcus aureus colonization/infection commonly causes treatment failure 2
If infection is confirmed, adding flucloxacillin (or erythromycin if penicillin-allergic) before or concurrent with topical calcineurin inhibitor therapy is recommended 2
The British Medical Journal suggests using soap-free cleansers exclusively to avoid further lipid stripping and barrier disruption 2
Short-term sedating antihistamines at bedtime may help break the itch-scratch cycle if pruritus is severe, though they have minimal direct anti-itch benefit 2

The British Medical Journal notes that potent topical corticosteroids (Class II-III) are significantly more effective than moderate-potency agents for moderate eczema, but facial use carries increased risk of skin atrophy and should be limited to short courses (typically 1-2 weeks) 2

Lack of improvement after appropriate use of moderate potency topical corticosteroids indicates the need for treatment modification 3

Guidelines recommend referral to a dermatologist when there is no improvement after appropriate first-line treatment 4, 5
A dermatologist can provide specialized assessment and develop a tailored treatment plan for refractory cases 5

Evaluate for secondary bacterial infection, which may be contributing to treatment failure 3
Consider patch testing to identify potential contact allergens that may be exacerbating the condition 5
Ensure proper skin care with appropriate soap-free cleansers and continued use of emollients 3, 6

Continue basic skin care, including use of soap-free cleansers 6 and application of fragrance-free emollients liberally, especially after bathing 3
Consider short-term oral antihistamines, such as sedating antihistamines, to help break the itch-scratch cycle if pruritus is severe 7
Reassess after 2 weeks, and if improvement is seen, continue treatment for a total of 4-6 weeks, otherwise proceed with dermatology referral 4